Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glabellar Lines Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids

NCT01583478
View directory record Official record
Conditions
Skin Aging, Elastosis Senilis
Interventions
incobotulinumtoxinA
Biological
Lead sponsor
The Maas Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 2 Interventional

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

NCT06411002
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
DAXXIFY
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

NCT00770211
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

NCT05100199
View directory record Official record
Conditions
Glabellar Lines
Interventions
OnabotulinumtoxinA X, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Glendale, Arizona • Los Angeles, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

NCT02677805
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo, Botulinum Toxin A - Open Label
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Encinitas, California • Aventura, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

NCT00512135
View directory record Official record
Conditions
Glabellar Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 units)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Los Angeles, California • Englewood, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines

NCT02184988
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum purified neurotoxin, Type A
Biological
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

NCT04225260
View directory record Official record
Conditions
Glabellar Lines, Lateral Canthal Lines
Interventions
botulinum toxin neuromodulator
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

NCT02334423
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

NCT03732833
View directory record Official record
Conditions
Lateral Canthal Lines, Glabellar Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03960957
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA, Placebo
Biological · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
11
States / cities
Redondo Beach, California • San Diego, California • Westport, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

NCT03806933
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
NT 201
Drug
Lead sponsor
Merz Aesthetics GmbH
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Encino, California • Newport Beach, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

NCT02939326
View directory record Official record
Conditions
Glabellar Frown Lines (GL)
Interventions
EB-001 injection, Placebo injection
Drug
Lead sponsor
Bonti, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Fremont, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

NCT04247074
View directory record Official record
Conditions
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Interventions
botulinum toxin neuromodulator, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Encino, California • Santa Monica, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

NCT06604832
View directory record Official record
Conditions
Skin Aging, Skin Wrinkling
Interventions
PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo)
Drug
Lead sponsor
Kalpna Kay Durairaj, MD, FACS
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jun 11, 2026, 5:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy Trial for the Reduction of Glabellar Lines

NCT02466178
View directory record Official record
Conditions
Rhytids in the Glabellar Region
Interventions
Serene RF System
Device
Lead sponsor
Serene Medical Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Palo Alto, California • San Mateo, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03736928
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA dose level 1 or 2, placebo, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
Biological · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
10
States / cities
Encino, California • Manhattan Beach, California • Vista, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

NCT03985982
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subject Satisfaction With AbobutulinumtoxinA Treatment

NCT03687736
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

NCT04096326
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Fremont, California • Santa Monica, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
Interventions
onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
Biological · Drug · Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006

NCT02428608
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
DWP-450 (Botulinum purified neurotoxin, Type A)
Biological
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jun 11, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014635
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Jun 11, 2026, 5:52 AM EDT